METTL3 and breast cancer: Recently, it was discovered that the oncoprotein hepatitis B X-interacting protein (HBXIP), whose aberrant expression drives the aggressiveness of breast cancer, releases the expression of METTL3 by repressing its inhibitor let-7 g [70].